Board of Directors
- Thomas J. Schall, Ph.D., President and CEO, ChemoCentryx, Inc.
- Regina E. Herzlinger, Ph.D., Professor of Business Administration Chair, Harvard Business School
- David V. Goeddel, Ph.D., Managing Partner, The Column Group
- Roger Lucas, Ph.D., Vice Chairman, Techne Corporation
- Edward E. Penhoet, Ph.D., Director of Alta Partners
- Samuel P. Wertheimer, Ph.D., OrbiMed Advisors, LLC
Thomas J. Schall, Ph.D.
President and CEO
One of the earliest investigators in the field of chemokine biology, Dr. Schall founded ChemoCentryx in 1997 to focus on the discovery and development of chemokine-based therapeutics. Prior to founding ChemoCentryx, Dr. Schall spent several years at a division of Schering Plough, the DNAX Research Institute, where he made fundamental contributions to the understanding of chemokines and their receptors in human in disease. Before that Dr. Schall served for some years as a scientist with Genentech, Inc. During his scientific career, Dr. Schall published over 100 book chapters and articles in noted peer-reviewed journals. In his business capacity, Dr. Schall has led ChemoCentryx through several rounds of major private equity and business development investment (>$150 million in total), in addition to raising significant amounts of non-dilutive funding (in excess of $24 million) through such sources as DARPA and the NIH / NIAID. He has overseen the company's development of a wide pipeline of drug candidates in clinical trials and preclinical development. Dr. Schall received his Ph.D. in Cancer Biology at Stanford University.
^ Return to Top
Regina E. Herzlinger, Ph.D.
Professor of Business Administration Chair, Harvard Business School
Regina E. Herzlinger is the Nancy R. McPherson Professor of Business Administration Chair at the Harvard Business School. She was the first woman to be tenured and chaired at Harvard Business School. Dr. Herzlinger is widely recognized for her innovative research in health care, including her early predictions of the unraveling of managed care and the rise of market and consumer-driven health care and health care focused factories, two terms that she coined. She has authored a number of books, including Consumer-Driven Health Care: Implications for Providers, Payers and Policymakers, Market-Driven Health Care and Financial Accounting and Managerial Control of Nonprofit Organizations. Her numerous articles have been featured in a variety of publications, including the Journal of the American Medical Association, Modern Healthcare, Circulation, Healthcare Financial Management, Harvard Business Review, The Economist and The Wall Street Journal.
Dr. Herzlinger has served as a board member of many publicly-traded firms, most of which are in the health care sector. Dr. Herzlinger is currently on the board of WellCare Health Plans, Inc. Additionally, she has served on the Scientific Advisory Group to the U.S. Secretary of the Air Force.
Dr. Herzlinger has been the recipient of several awards, including the Harvard Business School outstanding teacher award, the American College of Healthcare Executives?Hamilton Book of the Year award, the Healthcare Financial Management Association’s Board of Directors award and Management Accounting's research prize. In addition, Modern Healthcare readers selected her as one of 2003's, 2004's and 2005's "100 Most Powerful People in Healthcare" and Managed Healthcare named her as one of health care’s top ten thinkers. She received her Bachelor’s Degree from MIT and her Doctorate from the Harvard Business School.
^ Return to Top
David V. Goeddel, Ph.D.
Managing Partner, The Column Group
Dr. Goeddel has served as a member of our board of directors since March 1999. Since February 2007, Dr. Goeddel has been a managing partner of The Column Group, a venture capital fund.
From June 2006 to February 2007, Dr. Goeddel was an independent consultant. From August 2004 to June 2006, Dr. Goeddel served as Senior Scientific Vice President for Amgen Inc. (following Tularik's acquisition by Amgen in 2004). Dr. Goeddel co-founded Tularik in November 1991, and served as its Chief Executive Officer from April 1996 until August 2004 and as its Vice President of Research from 1993 to 1996.
From 1978 to 1993, Dr. Goeddel worked at Genentech, Inc., most recently as Genentech Fellow and Director of Molecular Biology.
Dr. Goeddel received his B.A. in chemistry from the University of California, San Diego, and his Ph.D. in biochemistry from the University of Colorado. Dr. Goeddel also performed postdoctoral research at the Stanford Research Institute.
^ Return to Top
Roger Lucas, Ph.D.
Vice Chairman, Techne Corporation
Dr. Lucas is a Director of Techne Corporation, a Series A investor in ChemoCentryx. A founding member of the staff at R&D Systems, now a division of Techne, Dr. Lucas guided that company's marked growth over 10 years, where he was a principal architect of R&D Systems' innovative deal making and acquisition of key competitors.
Techne Corporation, through its two R&D Systems subsidiaries, is the world's largest manufacturer and supplier of immunoregulatory molecules to the biomedical research community.
Dr. Lucas also sits on the Board of St. Croix Medical, Discovery Genomics, Zelo Technologies, Printware and Visual Circuits.
^ Return to Top
Edward E. Penhoet, Ph.D.
Director of Alta Partners
Edward E. Penhoet, Ph.D. has served as a member of our board of directors since December 2007. Since August 2000, Dr. Penhoet has served as a director of Alta Partners, a venture capital partnership investing in information technologies and life science companies. From July 1998 until July 2002, Dr. Penhoet served as the Dean of the School of Public Health and as a Professor of Public Health and of Molecular and Cellular Biology at the University of California, Berkeley. Dr. Penhoet was a co-founder of the Chiron Corporation, a biotechnology company, where he served as President, Chief Executive Officer and a director from its formation in 1981 until April 1998. From 1971 until 1981, Dr. Penhoet was a faculty member of the Biochemistry Department at the University of California, Berkeley. Since September 2004, Dr. Penhoet has served as President of the Gordon and Betty Moore Foundation. From July 2002 to September 2004, he served as its Chief Program Officer, Science and Education. Since December 2004, Dr. Penhoet has served as the Vice Chairman of the Independent Citizens Oversight Committee of the California Institute of Regenerative Medicine. Dr. Penhoet currently serves as a director of Renovis, Inc., a biopharmaceutical company, Zymogenetics, Inc., a biotechnology company, and several privately held companies. Dr. Penhoet received an A.B. in biology from Stanford University and a Ph.D. in biochemistry from the University of Washington. From 1968 until 1970, Dr. Penhoet was a post-doctoral fellow at the University of California, San Diego.
^ Return to Top
Samuel P. Wertheimer, Ph.D.
OrbiMed Advisors, LLC
Dr. Wertheimer assumed a role on the ChemoCentryx Board in 2001 with the participation of OrbiMed as the lead investor in the Company's Series B financing. Dr. Wertheimer joined OrbiMed Advisors LLC in 2000 as a senior analyst covering private equity and small capitalization biotechnology companies.
Dr. Wertheimer was previously Director, Office of Industrial Liaison at the New York University School of Medicine. From 1996 to 1998, Dr. Wertheimer was a Director of Technology Assessment at Paramount Capital Investments, LLC, an investment group specializing in the biotechnology industry.
Dr. Wertheimer received a Ph.D. in Molecular Biology from New York University, an M.P.H. from Yale University and a B.A. from The Johns Hopkins University. Dr. Wertheimer serves on the boards of several privately held biotechnology companies.
^ Return to Top
|
